Aug 04,2021

Decisions on eye level in cancer therapy

In order to support those affected in actively shaping their therapy, the Berlin digital healthcare company Fosanis is now offering an interactive course program in the Mika app. Mika is the first digital health application (DiGA) that can be prescribed for all types of cancer by medical and psychotherapeutic professionals. In the so-called "Making decisions" theme trip, those affected can practice making therapy decisions in dialogue with the treatment team. 2 proven experts accompany users through the individual stages with video messages. The psychologically-oriented theme trips are a central component of the Mika app and are developed together with cancer patients, doctors, psychotherapists and many other experts from oncology.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 01,2021

Vinehealth listed as Top 25 HealthTech startups

Healthcare technology startups have come to the forefront over the past year and will continue to dominate public interest for several years to come. Read more about this feature. Vinehealth announced that the company is selected to be in the list of Top 25 Healthtech startups by Splento.

View Analyst & Ambassador Comments
Go to original news
Aug 23,2021

Kaiku Health to present research with Docrates Cancer Center and Hirslanden Institut für Radiotherapie at ESTRO 2021

New research by Kaiku Health, Docrates Cancer Center, and Hirslanden Institut für Radiotherapie Aarau will be presented at ESTRO 2021 as a poster discussion. This year, the congress is organized as a hybrid event and the poster session takes place online. Presented by Juha Kononen from Docrates Cancer Center, the poster shares insights into the use of machine learning in predicting patient-reported symptoms during breast and prostate radiotherapy.

View Analyst & Ambassador Comments
Go to original news
Aug 26,2021

Data MATRIX Introduces an AI-Operated Patient Survival Assessment Tool

Data MATRIX, a sole Real-World Evidence solutions provider in Russia, has presented a predictive analytics tool for estimating patient survival based on Real-World Data. An important feature of the presented tool for predictive analysis of Real-World Data is its countrywide potential, and the ability to collect and analyze data on different patient cohorts. The company's medical director, Polina Shpigotskaya, held a live demonstration of the tool's capabilities to the participants, using breast cancer patients as an example. However, the product is also suitable for other therapeutic areas.

PRODUCT

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Aug 13,2021

Deep Learning Model Classifies Brain Tumors with Single MRI Scan

A team of researchers at Washington University School of Medicine have developed a deep learning model that is capable of classifying a brain tumor as one of six common types using a single 3D MRI scan, according to a study published in Radiology: Artificial Intelligence.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Aug 11,2021

Siemens Healthineers Adds Pathway for Lung Cancer to its AI-based Clinical Decision Support Software

Siemens Healthineers presents its second pathway for its AI-Pathway Companion at the Healthcare Information and Management Systems Society Global Health Conference 2021 (HIMSS 21). This new pathway is focused on non-small cell lung cancer, supporting personalized and standardized decision-making along the whole treatment process. The AI-Pathway Companion Lung Cancer assists multidisciplinary teams (MDT) by facilitating patient management and case reviews in a single dashboard, providing quality checks on data completeness, and enabling the documentation of clinically relevant patient-specific notations.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Aug 20,2021

Novel AI Blood Testing Technology can ID Lung Cancers with High Accuracy

A novel artificial intelligence blood testing technology developed by researchers at the Johns Hopkins Kimmel Cancer Center was found to detect over 90% of lung cancers in samples from nearly 800 individuals with and without cancer.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Aug 18,2021

Bristol Myers Squibb Exercises Option to Develop Exscientia's AI-Designed, Immune-Modulating Drug Candidate

Exscientia, a clinical-stage, artificial intelligence (AI)-driven pharmatech company, today announced that Bristol Myers Squibb has elected to in-license an immune-modulating drug candidate created by Exscientia. Exscientia has two active collaborations with Bristol Myers Squibb, which together focus on multiple therapeutic areas, including oncology and immunology. A significant expansion of the relationship was announced earlier this year.

COLLABORATION PARTNERSHIP

#data & technology

#ai/software

#platform

View Analyst & Ambassador Comments
Go to original news
Aug 01,2021

Pharmacogenomics in cancer supportive care: key issues and future directions

The complexity of cancer care has changed dramatically in the past decade. Advances in genomic science and proteomics have resulted in approvals of companion diagnostics, next-generation sequencing (NGS) platforms, and novel immunotherapies and targeted therapies, which offer more precise treatments in contrast to the “one-size-fits-all” chemotherapy model. Researchers focus on the clinical challenges and opportunities for effective supportive care, resulting from recent advances in pharmacogenomics.

CLINICAL STUDY

#cdx

View Analyst & Ambassador Comments
Go to original news
Aug 04,2021

Evaluation of a new online cognitive assessment tool in breast cancer survivors with cognitive impairment: a prospective cohort study

Currently cancer-related cognitive impairment (CRCI) is mainly assessed by means of questionnaires, which is very laborious for the patients and the supervising physician. Researchers evaluated a new online cognitive assessment tool, the MyCognition Quotient (MyCQ, Cambridge) in breast cancer survivors with CRCI, and compared the results with a psychometric test measuring cognitive complaints, depression, and anxiety.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY